Cardiovascular disease: risk assessment and reduction, including lipid modification
In development [GID-NG10178] Expected publication date: 19 April 2023
Search results
592 results
-
-
Type 1 diabetes in adults: diagnosis and management (update)
In development [GID-NG10159] Expected publication date: TBC
-
Shared decision making
In development [GID-NG10120] Expected publication date: 17 June 2021
-
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1332]
In development [GID-TA10272] Expected publication date: 14 July 2021
-
Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674]
In development [GID-TA10543] Expected publication date: TBC
-
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma ID1352
In development [GID-TA10319] Expected publication date: TBC
-
Luspatercept for treating anaemia caused by myelodysplastic syndromes [ID1550]
In development [GID-TA10508] Expected publication date: TBC
-
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
In development [GID-TA10623] Expected publication date: TBC
-
Nivolumab with ipilimumab for untreated PD-L1 mutation-positive non-small-cell lung cancer [ID1675]
In development [GID-TA10585] Expected publication date: TBC
-
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]
In development [GID-TA10490] Expected publication date: TBC
-
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]
In development [GID-TA10492] Expected publication date: TBC
-
Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]
In development [GID-TA10567] Expected publication date: 24 November 2021
-
Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714]
In development [GID-TA10590] Expected publication date: 19 May 2021
-
Liraglutide for managing obesity in people aged 12 to 17 [ID1630]
In development [GID-TA10563] Expected publication date: TBC
-
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma [ID2709]
In development [GID-TA10579] Expected publication date: TBC
-
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia ID1494
In development [GID-TA10424] Expected publication date: TBC
-
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer [ID1665]
In development [GID-TA10550] Expected publication date: TBC
-
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 1 systemic therapy [ID1684]
In development [GID-TA10580] Expected publication date: TBC
-
Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin lymphoma [ID1685]
In development [GID-TA10578] Expected publication date: TBC
-
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596
In development [GID-TA10497] Expected publication date: TBC
-
Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer [ID3756]
In development [GID-TA10631] Expected publication date: TBC
-
Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353
In development [GID-TA10320] Expected publication date: TBC
-
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]
In development [GID-TA10620] Expected publication date: TBC
-
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]
In development [GID-TA10489] Expected publication date: TBC
-
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]
In development [GID-TA10377] Expected publication date: TBC
-
ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]
In development [GID-TA10259] Expected publication date: TBC
-
Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy ID1147
In development [GID-TA10343] Expected publication date: TBC
-
Lysosomal acid lipase deficiency - sebelipase alfa [ID737]
In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC
-
Afamelanotide for treating erythropoietic protoporphyria [ID927]
In development [GID-HST10009] Expected publication date: TBC
-
Third molars (impacted) - prophylactic removal [ID898]
In development [GID-TAG525] Expected publication date: TBC
-
Multiple sclerosis - sativex [ID387]
In development [GID-TAG368] Expected publication date: TBC
-
Managing common infections - antimicrobial prescribing guidelines
In development [GID-NG10050] Expected publication date: TBC
-
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)
In development [GID-MT526] Expected publication date: TBC
-
Skin abscess: antimicrobial prescribing
In development [GID-NG10163] Expected publication date: TBC
-
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID3775]
In development [GID-TA10636] Expected publication date: TBC
-
Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473]
In development [GID-HST10026] Expected publication date: 25 March 2021
-
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [ID1536]
In development [GID-TA10466] Expected publication date: 28 April 2021
-
Ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) [ID1530]
In development [GID-TA10564] Expected publication date: TBC
-
Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]
In development [GID-TA10363] Expected publication date: TBC
-
Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]
In development [GID-TA10609] Expected publication date: TBC
-
Sapropterin for treating phenylketonuria [ID1475]
In development [GID-TA10378] Expected publication date: 21 April 2021
-
Tebentafusp for treating metastatic HLA-A*02:01 positive uveal melanoma (ID1441)
In development [GID-TA10428] Expected publication date: 04 May 2022
-
Atezolizumab monotherapy for untreated PD-L1 positive metastatic non-small-cell lung cancer [ID1678]
In development [GID-TA10587] Expected publication date: 02 June 2021
-
Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer ID1509
In development [GID-TA10413] Expected publication date: TBC
-
Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]
In development [GID-HST10032] Expected publication date: TBC
-
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs [ID1658]
In development [GID-TA10561] Expected publication date: TBC
-
Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]
In development [GID-HST10033] Expected publication date: TBC
-
Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]
In development [GID-TA10653] Expected publication date: TBC
-
Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782]
In development [GID-TA10635] Expected publication date: TBC
-
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]
Technology appraisal [TA582] Published date: 24 May 2019